Copenhagen, 2016-05-13 09:00 CEST (GLOBE NEWSWIRE) -- Exiqon A/S, listed on NASDAQ Copenhagen (“EXQ”), has been informed that Morgan Stanley & Co. International plc after buy of shares owns 1,852,556 shares corresponding to 5.02% of the share capital and the voting rights in Exiqon A/S.
Additional information
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)
About Exiqon
Exiqon operates in two business areas: Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences. Exiqon is listed on NASDAQ in Copenhagen. For more information about us, please visit www.exiqon.com
